Abstract Purpose: The origins of expression microarray and reverse transcription-PCR (RT-PCR) signals in human saliva were evaluated. Experimental Design: The ''RNA'' extracts from human saliva samples were treated with vehicle, DNase, or RNase. Two-step amplification and hybridization to Affymetrix 133A cDNA microarrays were then done. Confirmatory RT-PCR experiments used conventionally designed PCR primer pairs for the reference housekeeper transcripts encoding 36B4, h-actin, and glyceraldehyde-3-phosphate dehydrogenase (GAPDH) mRNA sequences, which are known to be homologous to genomic DNA pseudogene sequences. Negative controls included the omission of reverse transcriptase (''no-RT'') to detect any DNA-derived signal. Finally, an RNA-specific RT-PCR strategy eliminated confounding signals from contaminating genomic DNA. Results: Microarray experiments revealed that untreated, DNase-treated, and RNase-treated ''RNA'' extracts from saliva all yielded negligible overall signals. Specific microarray signals for 36B4, h-actin, and GAPDH were low, and were unaffected by RNase. Real-time quantitative RT-PCR reactions using conventional, non^RNA-specific primers on saliva samples yielded PCR products for 36B4, h-actin, and GAPDH; DNase-treated saliva samples did not yield a PCR product, and the ''no-RT'' and ''+RT'' conditions yielded similar amounts of PCR product. The RNA-specific RT-PCR strategy, across all conditions, yielded no PCR product from saliva. Conclusions: The combination of (a) a minimal microarray signal, which was unaffected by RNase treatment, (b) the presence of a conventional RT-PCR housekeeper product in both RNase-treated and no-RTsaliva samples, (c) the absence of a conventional RT-PCR housekeeper product in DNase-treated conditions, and (d) the absence of a RNA-specific RT-PCR product shows that any microarray or RT-PCR signal in the saliva must arise from genomic DNA, not RNA. Thus, saliva extracts do not support mRNA expression studies.
Large-scale human cancer studies for the assessment of functional genomics or gene-environment interactions require a reliable source of RNA that can be accessed with minimal invasiveness, and is compatible with downstream, highthroughput applications. Options that have emerged include brush-exfoliated buccal cells (1) , urine (2) , and saliva (3, 4) . Given the potential translational importance of mRNA expression biomarkers in such noninvasively acquired biospecimens, it is imperative that the RNA specificity of gene expression studies from these specimens be confirmed.
Many human transcripts have homologous sequences in nontranscribed genomic DNA sequences, remote from the structurally active coding genes, which are termed pseudogenes. Common examples include h-actin, glyceraldehyde-3-phosphate dehydrogenase (GAPDH), acidic ribosomal phosphoprotein P0 (36b4), hypoxanthine phosphoribosyl transferase, glutathione S-transferases M1 and P1, and glutathione peroxidase. These pseudogenes are intronless, often have poly(A) tails, and have extremely high homology with cDNA sequences.
Pseudogenes are very commonly the source of primerconfounded, false-positive reverse transcription-PCR (RT-PCR) results from genomic DNA -contaminated total RNA extracts (5) . Although the use of DNase treatment of the ''RNA'' extract is a simple approach to the elimination of genomic DNA contamination, it has been shown to be both incompletely effective and to compromise the RNA-derived RT-PCR signal yield, particularly in trace mRNA template situations (1, 5) . 5 To circumvent this problem, we have developed an RNA-specific RT-PCR strategy that amplifies RNA specifically in a mixed nucleic acid background. The sensitivity of our method is equivalent to that of conventional RT-PCR, and is compatible with current real-time quantitative RT-PCR methods (1, 5 -7) .
In microarray transcriptome studies, the fluorescent signal may be RNA-specific or RNA-nonspecific, depending on the 5 Unpublished results. particular steps used for RNA isolation, template amplification, and labeling. Because published microarray data generally do not typically address RNA specificity, there is a presumption that T7-tagged odT-based reverse transcription and subsequent cRNA amplification by in vitro transcription approaches yield RNA-specific signals (Affymetrix Expression Analysis Technical Manual, p. 2.1.5, available from: http://www.affymetrix.com/; Arcturus RiboAmp manual, p. 11). The processes also entail an intermediate step of random primed cDNA ) double-stranded cDNA. These amplification approaches have some potential to produce false-positives due to carry-over double-stranded genomic DNA pseudogene sequence contaminants. As noted, these DNA sequences are incompletely extinguished by DNase treatment of the original RNA extract.
In addition, homologous genomic DNA or RNA sequences from mouth microorganisms (bacteria and viruses) could potentially confound gene expression studies that have not been designed to specifically exclude this possibility.
In this report, we evaluate the ability of saliva to reliably support gene expression studies by analyzing whether the microarray or RT-PCR signal previously reported by other laboratories does indeed arise from the RNA template, or alternatively, whether it arises from genomic DNA contaminants. Experiments using reciprocal RNase and DNase treatments of the saliva extract, omission of the reverse transcription step, and employment of a previously developed RNA-specific RT-PCR strategy definitively show the origin of both the microarray signal and the RT-PCR signal.
Materials and Methods

Human saliva collection
Volunteer subjects were recruited anonymously, as per Institutional Review Board -approved protocols. Individual saliva samples for each of the five healthy volunteers were processed separately. Each spontaneous, unstimulated 3 to 5 mL saliva specimen was expectorated into a tube containing 10 mL of RNAlater (Ambion, Inc., Austin, TX), as per Li and coauthors (4) , and placed immediately on ice at 4jC.
Overall strategy
In separate saliva specimens from each individual processed in parallel, mRNA expression was qualitatively and quantitatively evaluated by both cDNA microarray (human genome U133A array; Affymetrix, Inc., Santa Clara, CA) and real-time RT-PCR. Each RNA extract was divided into three separate treatments: untreated, DNasetreated, and RNase-treated representing the hypothesized RNA/DNA mixture, pure RNA if present in saliva, and pure genomic DNA contaminant if present in saliva, respectively. Commercially available human lung total RNA (Clontech, Mountain View, CA) was used as positive control RNA.
For microarray experiments, the amounts of RNA (in the microgram range) required for conventional amplification and labeling prompted the use of a GeneChip Two Cycle Target Labeling kit (Affymetrix), which gives sufficient cRNA yield from a total RNA quantity as low as 10 to 100 ng. Two rounds of cDNA synthesis prior to in vitro transcription and labeling allow higher amplification than is achievable with other protocols.
The RT-PCR experiments used standard-design primers as well as mRNA-specific primer pairs ( Table 1 ). The expression of three reference housekeeper transcripts, 36B4, h-actin, and GAPDH, was measured under all three RNA treatment conditions using two types of primer sets: (a) a standard-design primer set (in which at least one oligomer spans an exon/exon splice site), that can coamplify both RNA template and the corresponding contaminating genomic DNA pseudogenes for these transcripts, and (b) an RNA-specific RT-coupled PCR primer set previously shown to be RNA-specific (5) . As further controls, reverse transcription reactions either included the reverse transcriptase enzyme (RT+), or omitted the enzyme (''no-RT''); the latter therefore amplified only contaminating genomic DNA.
RNA isolation from saliva
Individual saliva samples for each of the five volunteers were immediately centrifuged at 2,600 Â g for 15 minutes at 4jC. For saliva supernatant, total RNA was isolated from 500 AL of sample using the standard Qiagen RNeasy kit (Qiagen, Valencia, CA) with minor modifications to the manufacturer's protocol. Briefly, RLT-hME buffer (350 AL) was added to the saliva sample (500 AL) and vortexed for 10 seconds. Although the results for the supernatant are displayed, identical extraction procedures were employed for the saliva ''pellet'' and whole saliva samples. The lysate was homogenized by passage (10 times) through a 22-gauge needle. Poly(C) RNA carrier (1 Ag) was added to this lysate, followed by 350 AL of 70% ethanol. The sample was vortexed again for 10 seconds and was held at room temperature for 1 minute. The lysate was then transferred to a column provided in the kit and centrifuged at 10,000 Â g for 30 seconds. RW1 buffer (700 AL) was added to the column after the flow-through from the previous spin had been discarded, followed by centrifugation at 10,000 Â g for 30 seconds. RPE buffer (500 AL) was added after the * Where cDNA was generated with an oligo-dT RT primer, PCR amplification employed a standard-design PCR primer set for the respective housekeeper cDNA (e.g., 36B4 std PCR; standard-design (std) PCR primers). c Where cDNA was generated using the tagged URT primer, the resulting cDNA was amplified with UR-PCR primers compatible with that unique tag (5) . The Universal RT primer has the general formula 5 ¶XT n VVN, where X is the sequence 5 ¶-aacgagacgacgacagac-3 ¶, n = 21 thymidines; V is A, C or G; and N can be any nucleotide A, C, G or T. Universal reverse primer (UR) has a formula identical to X (5 ¶-aacgagacgacgacagac-3 ¶), patent pending. collection tube had been changed, and the sample was centrifuged at 10,000 Â g for 10 seconds before the final elution into RNase-free water. Each isolated RNA extract was divided into three equal volumes maintained on ice, for different treatments. One volume was left untreated, the second one was DNase-treated, and the third was treated with RNase, as described below.
DNase treatment
In an attempt to remove any contaminating genomic DNA, we treated RNA with 10 units of RNase-free DNase (Ambion) in a volume of 50 AL, and then incubated it at 37jC for 30 minutes. This was followed by the addition of 0.1 volume of DNase Inactivation Reagent, and incubation at room temperature for 2 minutes. The DNase Inactivation Reagent was subsequently removed by centrifugation at 10,000 Â g for 1 minute, followed by transfer of the RNA solution into a fresh tube. Given the published data demonstrating incomplete DNase efficacy (5), we did this DNase treatment twice for samples intended for both microarray analysis and RT-PCR.
RNase treatment
To further determine the relative contributions of DNA and RNA to the PCR product, we treated the isolated RNA solution with 1 AL of RNase A (4 mg/mL; Gentra Systems, Inc., Minneapolis, MN) and incubated it at 37jC for 30 minutes. RNase was removed from the RNA solution by use of a RNA cleanup protocol described by the manufacturer (RNeasy Mini Handbook, Qiagen).
Microarray analysis
RNA isolated from saliva, as well as the human lung total RNA standard purchased from Clontech, was either left untreated or treated with DNase or RNase, with cleanup as described above. An Agilent Capillary Bioanalyzer 2100 (Agilent Technologies, Palo Alto, CA) was used to assess the RNA quality of each treatment condition in both RNA types. One cycle of double-stranded cDNA synthesis was done using the GeneChip Two Cycle Target Labeling kit (Affymetrix) for all of the treated and untreated RNA samples. This was followed by in vitro transcription amplification of antisense RNA (cRNA) using the MEGA script T7 kit (Ambion). The samples were then subjected to a second cycle of cDNA synthesis, followed by biotin labeling of antisense cRNA. Subsequently, the labeled RNA samples were hybridized, washed, stained, and then scanned using an Affymetrix GCS 3000 scanner, housed in the Genomics Microarray Core facility at the Wadsworth Center. GeneSpring GX software (Agilent) was used for data normalization and initial data analysis.
Conventional RT-PCR
Reverse transcription. The Superscript II reverse transcriptase RNase H À (Invitrogen Life Technologies, Inc., Carlsbad, CA) protocol, with minor modifications, was followed, to reverse transcribe both treated and untreated RNA. All steps were done in a thermal cycler [PerkinElmer 9700 or real-time LightCycler (Roche, Indianapolis, IN), as appropriate]. cDNA was prepared in a 20 AL reaction containing 1 AL of oligo(dT) (0.5 Ag/AL), RNA (up to 0.3 Ag), and RNase-free/DNase-free water to make up the final volume to 11 AL. The RNA was denatured at 65jC for 5 minutes and then at 4jC for 5 minutes, before the addition of the following: 4 AL of 5Â Superscript II first strand buffer (Invitrogen Life Technologies), 2 AL of 0.1 MDTT, and 2 AL of deoxynucleoside triphosphate mix (10 mmol/L). Incubation at 42jC for 2 minutes was followed by the addition of 1 AL of Superscript II RT to each tube, and each tube was individually mixed gently by pipetting up and down. In the no-RT reactions, 1 AL of water was added instead of the reverse transcriptase. This was followed by incubation at 42jC for 50 minutes, and then at 70jC for 15 minutes.
Quantitative real-time cDNA-PCR protocol. Real-time quantitative RT-PCR was done using SYBR Green chemistry (Molecular Probes, Invitrogen). The following were added in a glass capillary (Roche) for a final reaction volume of 25 AL: 5.0 AL of the 5Â one-step RT-PCR buffer (Qiagen), to yield 2.5 mmol/L of MgCl 2 ; 15.5 AL of RNase-free/DNasefree H 2 O; a total of 1.6 AL of deoxynucleoside triphosphate mix (10 mmol/L each triphosphate nucleotide); 1.25 AL of SYBR Green dye (1:10,000); 0.4 AL of Platinum Taq (Invitrogen Life Technologies) DNA polymerase; 0.25 AL of 50 Amol/L from each oligo of the primer pair; and 1.0 AL template cDNA from the reverse transcriptase reaction. The thermocycling reaction conditions included one denaturing cycle (20jC/s up-ramp) at 95jC for 30 seconds; PCR for 50 cycles consisting of up-ramp (20jC/s) to melt at 95jC for 10 seconds, down-ramp (3.5jC/s) to anneal at 59jC; and up-ramp (3.5jC/s) to anneal at 72jC for 30 seconds. The melting analysis for one cycle was as follows: upramp (20jC/s) to melt at 95jC for 10 seconds, down-ramp (20jC/s) to anneal at 58jC/s, and then slow up-ramp (0.1jC/s) for continuous acquisition to 95jC. For a run to be scored as positive, and for quantitative data to be entered, the PCR product had to display both a single peak with characteristic melt temperature on LightCycler melting analysis, and to be corroborated by agarose EtBR electrophoresis, displaying a single product at the appropriate size.
RNA-specific RT-PCR
Parallel experiments were done employing an RNA-specific RT-PCR technique, as previously described (1, 5 -7). Briefly, the approach was to take conventional total RNA extracts, which invariably also contain genomic DNA contamination, and to reverse-transcribe the poly(A)-containing mRNA with a 5 ¶-tagged and 3 ¶-anchored oligo-dT reverse transcription primers (100 Amol/L; URT). The unique 5 ¶ tag sequence does not occur anywhere in the human genome, so that with the poly(T) region annealing to poly(A)-capped RNA, only RNA-derived cDNA is uniquely tagged, whereas genomic DNA is not. The subsequent PCR step uses a reverse (antisense) primer (UR) targeting this tag, and a transcript-specific forward (sense) primer. Therefore, only those DNA sequences derived from mRNA containing the tag (i.e., cDNA) are amplified. The method does not require DNase treatment of the original nucleic acid extract for RNA specificity.
Thus, cDNA synthesis for RT-PCR was done accordingly in two parallel sets of samples, using either a conventional oligo-dT primer, or alternately, the tagged URT primer as an RNA-specific control. Housekeeper reference transcripts (36b4, h-actin, and GAPDH; GAPDH results not shown) were amplified using standard-design housekeeper cDNA primers when the cDNA template was prepared with oligo-dT primer, whereas UR (tag compatible) reverse primer pairs were used when cDNA was generated using the tagged-RT primer. Primer sets used in both the conventional and RNA-specific RT-PCR are listed in Table 1 .
Results
RNA quality
For the RNA (Clontech) standard, the electropherograms obtained from the Agilent Bioanalyzer 2100 gave clear and well-defined 28S and 18S RNA peaks, with high 28S/18S RNA ratio for the untreated and DNase-treated RNA standards. The RNase-treated Clontech RNA standard showed complete degradation of the RNA. For the saliva RNA extracts, the bioanalyzer did not detect meaningful 28S/18S bands (data not shown).
Microarray results
The overall HG U133A microarray patterns were used to initially screen for the presence or absence of RNA in both the RNA standard and the saliva extract samples (Fig. 1) . Additionally, signals from the internal reference housekeeper genes [ribosomal phosphoprotein large subunit P0 (36b4), h-actin, and GAPDH] in the untreated, DNase-treated, and RNasetreated fractions were used to assess the presence of DNA and RNA in the saliva samples. The Clontech human lung total RNA sample was used as a positive control (Fig. 2) .
For the known, pure total RNA (Clontech) standard, the untreated and DNase-treated conditions had 54.6% and 48.2% of probes displaying present signals, respectively, whereas the RNase-treated condition gave only a 5.9% present signal (Fig. 1) . For saliva RNA extracts, in comparison, untreated saliva RNA gave only 7.4% present signal and the DNase-treated condition gave only about 5.3% present signal, both of which were close in value to the RNase-treated condition of the control RNA. The RNase condition gave similar (8.1%) present signals. The low overall signal intensity for all saliva specimens can be visualized in the respective heat maps (Fig. 1) .
The microarray data were normalized using RMA normalization, a quantile normalization procedure that normalizes across all chips in a given set, in the GeneSpring GX software. The mean values obtained from the three probes (5 ¶, middle, 3 ¶ positions for h-actin and GAPDH) or the five probes (for the multiple 36b4 probe sets) were plotted against the treatment conditions (Fig. 2) . The RNA standard (Clontech) showed maximum signals in the untreated condition for all three housekeeping genes; there was no significant decrease in the DNase-treated condition, whereas the RNase-treated condition showed a significant decrease in signal intensity. The untreated saliva RNA showed much lower signal intensities than did the untreated Clontech standard RNA (Fig. 2) . There was no significant difference between the RNase-treated condition of the Clontech standard RNA and the untreated saliva RNA. The difference between the untreated saliva extract and the RNasetreated saliva extract was not significant.
RT-PCR results
Quantitative RT-PCR was used to validate the microarray results. For the untreated saliva RNA extract (Figs. 3A and 4A), standard-design PCR product was present in both the RT and no-RT conditions, implying at least a contribution to the PCR product by contaminating a genomic DNA template of identical size, i.e., processed pseudogene sequence. When DNase was applied to each of the saliva RNA extracts, all PCR product signals were extinguished. When RNase was applied to the saliva RNA extract, PCR product signal was still preserved across RT and no-RT conditions. This implies that any positive signal for the salivary extracts was genomic DNA -contaminant in origin. Results were consistent across all five volunteers, and for the supernatant, ''whole saliva,'' and the centrifuged pellet fraction RNA extracts; results for the supernatant fraction are displayed (Figs. 3 -5) .
For the Clontech control RNA sample (Figs. 3B and 4B), the untreated and DNase-treated samples gave an RT product, but Fig. 1 . Overall heat maps of the hybridization of human RNA standard (lung total RNA, Clontech, top) and human saliva (bottom) to same-lot Affymetrix U133A expression microarrays. Each sample was partitioned into untreated, DNase-treated, and RNase-treated conditions. Present (%), number of probes displaying a signal above the Affymetrix software^defined threshold. For the RNA standard, DNase had no effect, whereas RNase quenched the overall signal, implying that the signal derives exclusively from RNA, as expected of an RNA standard. The saliva signals under all conditions were very low, similar to the signal from the RNase-treated signal of the RNA standard, and were largely unaffected by RNase treatment, implying a lack of RNA in the samples. there was no PCR product resulting from the no-RT conditions. DNase did not extinguish this signal, whereas RNase extinguished the signal completely.
We attempted to quantitate the amounts of RNA-derived signal, if any, using real-time RT-PCR employing untreated saliva RNA extracts coupled with standard-design transcript primers ( Fig. 3C shows 36B4 ; Fig. 4C shows h-actin) . In the no-RT condition, in which only homologous pseudogene-derived genomic DNA template is being amplified, there was consistently a higher quantity of original template (lower CRO) than in the ''RT'' condition, in which both RNA-and homologous pseudogene genomic DNA -derived signals are amplified. This result indicates that there is no incremental PCR signal detectable that is of RNA origin. Similarly, for RNase-treated Fig. 3. Electrophoresis gel display (A and  B) of real-time quantitative RT-PCR products, and real-time display (C) done on salivary RNA extracts (top, gel A) and positive RNA control (human lung commercial RNA standard; Clontech; bottom, gel B), under various conditions. A, using standard-design (std) 36B4 PCR primers, PCR products of untreated (Non), DNase-treated, and RNase-treated RNA extracts from saliva were compared using no-RTand RTconditions. MCF, positive control cDNA derived from a MCF-7 breast cancer cell line. B, Clontech RNA extracts subjected to conventional RT-PCR using the same primers as positive controls. C, real-time (LightCycler) curves of 36B4 (std) RT-PCR primer product from the nontreated total RNA extracts from saliva (A, top left), comparing those reverse transcription reactions containing reverse transcriptase (+RT) and omitted reverse transcriptase (no-RT) conditions. There is no detectable RNA-derived signal, implying that there is no lower starting template in the no-RTcondition, in which only genomic DNA is amplified, than in the RTcondition, in which both genomic DNA and RNA are amplified. Note that a lower CRO implies a higher amount of starting template, in which k / 2 (CRO) % (starting template). (A and B) of h-actin RT-PCR products, and real-time display (C) done on salivary RNA extracts under various conditions. A, using conventional h-actin (std) PCR primers; PCR products of untreated, DNase-treated, and RNase-treated total RNA extracts from saliva, comparing no-RT and RTconditions. B, Clontech RNA standard, as a positive control, was subjected to conventional (std) RT-PCR. Results for GAPDH were identical (data not shown). C, real-time (LightCycler) curves of h-actin (std) RT-PCR primer product from the nontreated total RNA extracts from saliva (A, top left), comparing those reverse transcription reactions containing reverse transcriptase (RT) and omitted reverse transcriptase (no-RT) conditions. There is no detectable RNA-derived signal, implying that there is no lower starting template in the no-RTcondition, in which only genomic DNA is amplified, than in the RTcondition, in which both genomic DNA and RNA are amplified. Note that a lower CRO implies a higher amount of starting template, in which k / 2 (CRO) % (starting template). When the RNA-specific strategy was used for RT-PCR, the mRNA-specific primers yielded no detectable product in any of the three treatments of the salivary RNA extracts across all conditions and all five individuals (Fig. 5A and B) .
Fig. 4. Electrophoresis gel display
Discussion
There is an intensive search ongoing to identify noninvasively acquired biological fluids that can serve as surrogates for adjacent or distant visceral cancer-prone organs. Saliva is one such candidate body fluid. Recently Li and coauthors (3, 4) reported the use of salivary transcriptome diagnostics as well as RT-PCR in oral cancer detection. In the current study, we were unable to corroborate their assertion that saliva reliably supports RNA-specific amplification strategies by microarray or RT-PCR. In exploring the discrepancies between our saliva microarray and RT-PCR studies, and those of Li and coauthors (3, 4) , we expended considerable effort to identify the origins of the signal.
Our microarray results indicate that saliva has no detectable RNA. Whereas for the Clontech control RNA standard, the hybridization signal was abolished with RNase treatment, there was very little signal loss when DNase treatment was used ( Figs. 1 and 2 ). That pattern stands in contrast with the stability of the microarray signal intensity in saliva extracts treated with RNase ( Figs. 1 and 2) . The fact that the saliva signal was not abolished after RNase treatment suggests that whatever low concentration of nucleic acid was present in saliva was DNA in nature. It should be noted that the specificity of microarrays for RNA-derived signal has been under-studied; reliance on the efficacy of DNases (3 -5) , and on conventional probe design, is commonly assumed to be sufficient to ensure RNA specificity.
The results of the RT-PCR studies were also unambiguous; we showed the genomic DNA origin of the signal arising in the RT-PCR. After the salivary RNA extract had been isolated by a standard solid phase technique (eukaryotic and nonviral), a comprehensive series of conditions were then applied to untreated saliva RNA extracts, including the subjection of parallel samples to reciprocal DNase or RNase treatments, as well as RT and no-RT conditions. Our results clearly indicate that the saliva RT-PCR signal originates from genomic DNA and not RNA; DNase abolished the entire signal, whereas RNase did not. In addition, the presence of a signal in the no-RT controls shows that the template cannot arise from RNA because there is no PCR amplification from RNA without the reverse transcription step. The lack of any signal from the mRNA-specific strategy further confirms that there is no detectable RNA transcript present in the saliva samples for the three highly expressed reference genes studied (36b4, h-actin, and GAPDH).
The lack of an apparent RNA-derived signal in this study is unlikely to be due to a lack of sensitivity; RT-PCR is widely accepted as the most sensitive method for measuring RNA, with high technical sensitivity (<5 transcript copies/cell), wide dynamic range of quantification (7-8 logarithmic decades), and high precision (<2% SD; ref. 8). Translationally, PCR-based methods are widely used in forensic and trace detection situations as the reference standard, and RT-PCR is capable of exquisitely sensitive cancer cell detection, down to one cancer cell per 10 6 normal cells (9, 10) . The specificity of many human sample RT-PCR assays remains open to question, due to the coamplification of carryover genomic DNA -derived pseudogene sequences that contaminate the cDNA mixture when conventional RNA extraction approaches are used in combination with conventional RT-PCR (5, (11) (12) (13) . The use of any generic RT primer, such as oligo-dT or random hexamers, renders the cDNA specificity of the reaction totally dependent on the specificity of the conventional PCR primer toward the cDNA sequence in question versus homologous genomic DNA sequence. The common, conventional approaches to the design of PCR primers for RT-PCR, such as the use of an individual oligomer spanning an exon/exon splice site, or the primer pair spanning an intron, however, are not sufficient to ensure mRNA-specific amplification in the context of homologous contaminating genomic DNA sequences in the reaction mix, as occurs for 36B4, h-actin, and GAPDH reference amplifications (5) .
There are several steps at which verification of the RNA specificity of a PCR product can be done. In the RT step, the reverse transcriptase can be omitted, yielding a PCR product that, if present, must be derived from genomic DNA. Similarly, parallel samples can be treated reciprocally with DNase (whereby only RNA-derived PCR products will be generated) or RNase (whereby only genomic DNA -derived PCR products Fig. 5 . Electrophoresis gel display of RNA-specific RT-PCR products, using the tagged URT primer set done on salivary RNA extracts under various conditions. A, using RNA-specific 36B4 (UR) PCR primers; PCR products of untreated, DNase-treated, and RNase-treated total RNA extracts from saliva, comparing no-RT and RTconditions. B, RNA-specific h-actin (UR) PCR primers; PCR products of untreated, DNase-treated, and RNase-treated total RNA extracts from saliva, comparing no-RTand RTconditions. There is no appropriate-size PCR product resulting from the use of either the 36B4 or h-actin cDNA-specific primer set.
will be generated). In addition, as previously shown by our laboratory (5), a tagged RT primer approach to reverse transcription of mRNA, and subsequent RT-coupled PCR, confer mRNA specificity to the quantitative PCR.
The quality of RNA is an important determinant of the reproducibility and relevance of subsequent quantitative RT-PCR experiments (14) , yet RNA is widely recognized as being more labile than DNA, due to ubiquitous RNases. Li and coauthors acknowledge the common presumption that human mRNA does not survive extracellularly in saliva, as the original motivation for their study to prove otherwise (3). Unfortunately, their study does not report control RT-PCR experiments, particularly for the reference internal housekeeper transcripts h-actin and GAPDH that they employed. Use of such controls might have addressed the RNA specificity of the RT-PCR in their saliva samples.
We cannot completely rule out the possibility that there was some potential for RNA-derived signals in that groups' microarray experiments. For example, conventional oral fluid (saliva) isolation can potentially be enhanced by the admixture of agitation-exfoliated buccal cells; brush-exfoliated buccal cell quantitative expression was first reported by our laboratory (1). It is therefore possible that more aggressive, unconventional oral fluid (saliva) collection techniques could have enhanced RNA yield. However, no such maneuvers were described (3). Furthermore, this should also have been apparent in the RT-PCR experiments that we attempted to replicate. Given the widely accepted idea that RT-PCR has much greater dynamic range and sensitivity than do microarray approaches, the absence of RNA-specific RT-PCR signals suggests that any RNA-derived signals must be below extraordinarily low detection limits.
It should be noted that RNA isolation in the studies of Li and coauthors (3) were done using a viral RNA isolation kit (QiaAmp, Qiagen), suitable for isolation of RNA from cell-free bodily fluids such as saliva. The protocol is not selective for human sequences over bacterial or viral sequences, nor for RNA over DNA, except to the extent that the use of DNase confers such specificity in the protocol. In view of the fact that most of the adult population harbors bacteria and viruses in saliva (15), we speculate that some of the signals reported by Li and coauthors (3) could potentially have been from bacterially or virally derived nucleic acids. For example, a BLAST search of several probe sequences present on the Affymetrix U133A chip that were used in the Li et al. (3) report for expression microarray -detected transcripts (e.g., DUSP1, IL-8, and GAPDH) showed close homology with DNA sequences from certain bacteria and viruses that are commonly found in human saliva (e.g., Streptococcus pyogenes and foot and mouth disease virus; http://www.ncbi.nlm.nih.gov/, accessed 9/22/2005). Therefore, false-positive microarray detection of such nonhuman sequences could have occurred, in addition to those derived from genomic DNA, in their study.
In conclusion, we found that there is no significant, intact human mRNA present in conventional saliva samples. The signal arising from microarray analysis is very low and likely nonspecific; the signal from RT-PCR in our study clearly originates from genomic DNA. Considerable caution should therefore be used in interpreting saliva-based mRNA expression studies. Because cancer diagnostics rely heavily on both the specificity of biomarker assays, and the quantitative nature of these markers' expression (16) , careful consideration of these technical validation issues is a prerequisite before resourceintensive clinical utility validation efforts are undertaken.
